Welcome to our dedicated page for OKYO Pharma news (Ticker: OKYO), a resource for investors and traders seeking the latest updates and insights on OKYO Pharma stock.
OKYO Pharma Limited develops investigational ophthalmic therapies for neuropathic corneal pain and inflammatory eye diseases. The company’s lead candidate, urcosimod, formerly OK-101, is described as a lipid-conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor, with development centered on ocular pain and inflammation.
Recurring company updates cover urcosimod clinical data, patient-reported outcomes from a completed Phase 2 study in neuropathic corneal pain, FDA IND and Fast Track status for the NCP program, scientific advisory and ophthalmology-conference presentations, ordinary-share ownership disclosures, and purchases of Nasdaq-listed ordinary shares by company insiders.
OKYO Pharma (Nasdaq: OKYO) filed its Annual Report on Form 20-F for the year ended March 31, 2026, and reported a strengthened cash position supporting its late-stage development plans. According to the company, it raised approximately $25 million during the fiscal year, including a February 2026 public offering generating about $22 million in gross proceeds.
OKYO reported cash and cash equivalents of roughly $20.6 million at March 31, 2026, which it expects will fully fund the FDA-agreed global Phase 3 NEPTUNE pivotal trial of urcosimod in neuropathic corneal pain. NEPTUNE, planned to start in the second half of 2026, will enroll about 111 patients in the US and Europe, randomized 2:1 to 0.05% urcosimod or placebo in a single-dose regimen and is designed as a potential registrational study following positive FDA Type D feedback.
OKYO Pharma (Nasdaq: OKYO) reported positive FDA Type D feedback supporting advancement of urcosimod into NEPTUNE, a global Phase 3 pivotal trial for neuropathic corneal pain (NCP). The FDA aligned on a single-dose study design and a potential single-trial registration pathway, subject to successful outcomes and continued review.
The NEPTUNE trial plans to enroll about 111 subjects, randomized 2:1 to 0.05% urcosimod versus placebo in the United States and Europe. OKYO intends to seek Breakthrough Therapy Designation to further accelerate development, building on urcosimod’s existing Fast Track status and open IND for NCP.
OKYO Pharma (Nasdaq: OKYO), a clinical-stage biopharma focused on neuropathic corneal pain and anterior segment eye diseases, will participate in a fireside chat at the Piper Sandler 2026 Virtual Ophthalmology Symposium.
The virtual event is scheduled for Thursday, July 9, 2026 at 8:30 AM ET, featuring CEO Robert J. Dempsey and CMO Flavio Mantelli, moderated by Biren Amin of Piper Sandler.
OKYO (Nasdaq: OKYO), a clinical-stage biopharma company focused on neuropathic corneal pain and inflammatory eye diseases, appointed Marta Sacchetti, MD, PhD to its Scientific Advisory Board.
She is an Associate Professor of Ophthalmology in Rome with prior global clinical development leadership in ophthalmology and neurotrophins. OKYO’s lead candidate urcosimod holds an IND and FDA Fast Track designation for neuropathic corneal pain.
OKYO (Nasdaq: OKYO) announced that CEO Robert J. Dempsey and CSO Raj Patil will present at upcoming scientific meetings in Denver in early May 2026.
Dempsey will speak at Eyecelerator on May 1, 2026. Patil will present ARVO data on May 5, 2026 reporting first-in-human results for urcosimod. Urcosimod holds an IND for neuropathic corneal pain and has FDA Fast Track designation.
OKYO Pharma (Nasdaq: OKYO) will hold a Scientific Advisory Board meeting at the 2026 ASCRS Annual Meeting and present Phase 2 urcosimod data on April 11, 2026.
The SAB will review urcosimod clinical data to guide the next trial, which the company plans to initiate in H1 2026. Urcosimod holds an IND specific to neuropathic corneal pain and has FDA Fast Track designation.
OKYO Pharma (NASDAQ: OKYO) announced that Panetta Partners Limited, an entity in which Executive Chairman Gabriele Cerrone has a beneficial interest, purchased 10,119 ordinary shares on NASDAQ at $1.59 on March 19, 2026, bringing his total holdings to 10,526,416 shares.
The transaction is an insider purchase and updates the chairman's aggregate beneficial ownership.
OKYO Pharma (NASDAQ: OKYO) said on March 19, 2026 that Non-Executive Director John Brancaccio purchased 5,000 ordinary shares on NASDAQ at $1.61 per share, increasing his total holding to 31,201 shares.
The disclosure reflects an insider purchase by a director in the company developing therapies for neuropathic corneal pain and inflammatory eye diseases.
OKYO Pharma (NASDAQ: OKYO) said Gary Jacob, Chief Development Officer and director, acquired 30,980 ordinary shares on NASDAQ at $1.59 on March 19, 2026, increasing his total holding to 108,920 shares.
The purchase is a direct insider buy by a senior officer and board member, showing personal investment in the company's clinical-stage programs for neuropathic corneal pain and inflammatory eye diseases.
OKYO Pharma (Nasdaq: OKYO) reported exploratory Phase 2a patient-reported quality-of-life (QoL) improvements with 0.05% urcosimod for neuropathic corneal pain (NCP). Treatment (n=6) showed greater mean improvements versus placebo (n=6) in emotional well-being, mood, and time spent thinking about eye pain.
Findings will be presented at ARVO 2026 and the company plans larger confirmatory Phase 2b/3 studies to validate these results.